Related Experiment Video

Updated: Jun 8, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Ridaforolimus

    Drugs in R&D
    |October 16, 2010
    PubMed

    Insights

    Ridaforolimus, an mTOR inhibitor, shows promise in treating various cancers, including sarcomas, breast, endometrial, lung, and prostate cancers. Clinical trials are evaluating its efficacy and development milestones for these conditions.

    Area of Science:

    • Oncology
    • Pharmacology

    Background:

    • Ridaforolimus (AP23573; MK 8669) is a sirolimus analog and a small molecule inhibitor of the mammalian target of rapamycin (mTOR).
    • It is being investigated for its potential in cancer treatment.

    Purpose of the Study:

    • To review the key development milestones of Ridaforolimus.
    • To discuss the therapeutic trials involving Ridaforolimus for various cancer types.

    Main Methods:

    • Review of clinical trial data and development milestones.
    • Analysis of Ridaforolimus's efficacy in different cancer indications.

    Main Results:

    • Ridaforolimus is in Phase III development for soft-tissue and bone sarcomas in the EU and US.
    • Phase II trials are ongoing for breast cancer, endometrial cancer, non-small cell lung cancer, and prostate cancer.

    Conclusions:

    • Ridaforolimus demonstrates potential as a therapeutic agent across a spectrum of cancers.
    • Further clinical evaluation is ongoing to establish its role in cancer treatment regimens.

    More Related Videos

    Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells08:47

    Monitoring eIF4F Assembly by Measuring eIF4E-eIF4G Interaction in Live Cells

    Published on: May 1, 2020

    Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs10:38

    Establishing 3-Dimensional Spheroids from Patient-Derived Tumor Samples and Evaluating their Sensitivity to Drugs

    Published on: December 16, 2022

    Related Concept Videos

    Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy01:26

    Extracorporeal Removal of Drugs: Continuous Renal Replacement Therapy

    Continuous Renal Replacement Therapy (CRRT) is an essential intervention for patients experiencing severe kidney dysfunction. This therapy offers a continuous mechanism for removing fluids and toxins from the bloodstream, leveraging the patient’s blood pressure to facilitate filtration through a specialized filter. This method contrasts with intermittent dialysis, providing a gentler and more consistent removal of waste products and excess fluid, which is particularly beneficial in critically...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    mTOR Signaling and Cancer Progression03:03

    mTOR Signaling and Cancer Progression

    The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
    The mTOR pathway or the...
    Renal Failure: Dose Adjustments01:11

    Renal Failure: Dose Adjustments

    In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
    Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
    However, dosage adjustments...
    Drugs for Treatment of Ulcerative Colitis in IBD01:29

    Drugs for Treatment of Ulcerative Colitis in IBD

    Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide generation. 
    Drug Elimination by Renal Route: Tubular Reabsorption01:22

    Drug Elimination by Renal Route: Tubular Reabsorption

    During the process of renal excretion, as the glomerular filtrate progresses to the distal convoluted tubule (DCT), drugs that are highly permeable, lipophilic, and nonionized undergo passive reabsorption from the tubular fluid into the surrounding peritubular capillaries. This reabsorption process restricts their elimination through the kidneys. However, the majority of drugs are either weak acids or weak bases, and their ionization level is dependent on pH. By altering the pH of urine, the...